Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does CERITINIB Cause Malignant neoplasm progression? 523 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 523 reports of Malignant neoplasm progression have been filed in association with CERITINIB (ZYKADIA). This represents 18.7% of all adverse event reports for CERITINIB.

523
Reports of Malignant neoplasm progression with CERITINIB
18.7%
of all CERITINIB reports
196
Deaths
156
Hospitalizations

How Dangerous Is Malignant neoplasm progression From CERITINIB?

Of the 523 reports, 196 (37.5%) resulted in death, 156 (29.8%) required hospitalization, and 20 (3.8%) were considered life-threatening.

Is Malignant neoplasm progression Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for CERITINIB. However, 523 reports have been filed with the FAERS database.

What Other Side Effects Does CERITINIB Cause?

Diarrhoea (452) Death (391) Nausea (381) Vomiting (270) Metastases to central nervous system (203) Non-small cell lung cancer (183) Fatigue (149) Decreased appetite (139) Dyspnoea (137) Disease progression (116)

What Other Drugs Cause Malignant neoplasm progression?

PEMBROLIZUMAB (10,111) NIVOLUMAB (9,363) ENZALUTAMIDE (4,696) CARBOPLATIN (4,177) EVEROLIMUS (3,789) PACLITAXEL (3,484) LETROZOLE (3,445) IPILIMUMAB (3,296) FULVESTRANT (3,221) LENVATINIB (2,929)

Which CERITINIB Alternatives Have Lower Malignant neoplasm progression Risk?

CERITINIB vs CERLIPONASE ALFA CERITINIB vs CERTICAN CERITINIB vs CERTOLIZUMAB CERITINIB vs CERTOLIZUMAB PEGOL CERITINIB vs CERTOPARIN

Related Pages

CERITINIB Full Profile All Malignant neoplasm progression Reports All Drugs Causing Malignant neoplasm progression CERITINIB Demographics